50% off Premium Yearly

OTCMKTS:RBGLY
Their pharmaceutical division is about 20% of their total revenues. 80% of the business is doing well but 20% is going to suffer a little bit when their big drug comes off patent. Watch the stock and see if there is an entry level a lower price from here. Very good company. Executes extremely well on the products that they have. Margins are high. Dividend growth over time is there.
Is it a good entry point after their big drug goes off-patent? When companies come off patent, it really comes down to the quality of the management team. This company’s management has done a terrific job at growing earnings, cash flow, dividends and sales. Doesn’t think it would be that great a concern that one of their drugs is coming off patent because they can just turned around given that they’ve got more of the consumer product business as a backdrop.
Reckitt Benckiser is a American stock, trading under the symbol RBGLY (previously RBGLY-OTC on Stockchase) on the US OTC (RBGLY). It is usually referred to as OTC:RBGLY or RBGLY
In the last year, no analyst issued a Buy, Sell, or Hold rating on RBGLY (previously RBGLY-OTC on Stockchase) on Stockchase. Read the latest expert commentary for Reckitt Benckiser.
Reckitt Benckiser was recommended as a Top Pick by Mark Grammer on 2007-08-13. Read the latest stock experts ratings for Reckitt Benckiser.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Reckitt Benckiser.
Reckitt Benckiser is covered by Stockchase experts and is worth watching.
On 2026-06-18, Reckitt Benckiser (RBGLY) stock closed at a price of $12.43.
Own this for defence. They've benefitted from inflation. Are getting into emerging markets which enjoy population growth, and in turn fuel company growth.